43781-74

Late phase II study of amrubicin in previously untreated patients with non-Hodgkin's lymphoma (NHL).

Subcategory: 
Category: 
Lymphoma and Plasma Cell Disorders
Session Type and Session Title: 
General Poster Session, Lymphoma and Plasma Cell Disorders
Abstract Number: 

8097

Citation: 
J Clin Oncol 28:15s, 2010 (suppl; abstr 8097)
Author(s): 
J. Suzumiya, K. Suzuki, N. Uike, F. Kawano, T. Takeo, S. Okamura, C. Sakai, M. Mori, K. Tamura, Amrubicin LYM Study Group; Shimane University Hospital, Izumo, Japan; Japanese Red Cross Medical Center, Tokyo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan; Yokkaichi Municipal Hostipal, Yokkaichi, Japan; National Hospital Organization Kyushu Medical Center, Fukuoka, Japan; Chiba Cancer Center, Chiba, Japan; Tama-Hokubu Medical Center, Tokyo, Japan; Fukuoka University, Fukuoka, Japan

Abstract Disclosures

Abstract: 

Background: We evaluated the efficacy and safety of amrubicin, a third generation synthetic anthracycline, in combination with cyclophosphamide, vincristine and prednisolone (ACOP) in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL). Methods: Previously untreated patients with intermediate or high grade NHL were treated with 8 cycles of amrubicin, 100 mg/m2, cyclophosphamide, 750 mg/m2, and vincristine, 1.4 mg/m2 (maximum 2.0 mg), on day 1, and prednisolone, 60 mg/m2/day day 1-5 every 21 days. Patients were evaluated for response and left ventricular ejection fraction (LVEF) every 2 cycles, and electrocardiogram at every cycle. The primary endpoint was response rate; secondary endpoints were survival, cardiac safety, and general safety. Results: Fifty-six patients were eligible and received a median of 8 treatment cycles. The median follow- up period was 57.1 months. Most patients had diffuse large B-cell lymphoma (76.8%). The response rate was 92.9%; the complete response (CR) and CRu rate was 69.6%. The 2- and 5-years survival rates were 76.2% and 58.7%, respectively. Reversible myelosuppression was the most common adverse event. Grade 3/4 neutropenia, anemia, thrombocytopenia and febrile neutropenia were reported in 82.5%, 19.3%, 8.8% and 7% of patients, respectively. There were no treatment-related deaths or patients experiencing cardiomyopathy. LVEF did not change during the course of treatment. Conclusions: The response rate and survival in non-Hodgkin's lymphoma patients treated with ACOP were comparable to those achieved with CHOP in other studies, but ACOP had virtually no reduction of LVEF up to a cumulative amrubicin dose of 800 mg/m2. This suggests that amrubicin has little chronic cardiotoxicity. ACOP should be evaluated in combination with rituximab (R) and then compared to R-CHOP.